Development of new therapy using novel chimeric oncolytic adenoviruse vector for intractable bladder cancer.
Project/Area Number |
23592354
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Hyogo Medical University |
Principal Investigator |
GOTOH Akinobu 兵庫医科大学, 医学部, 教授 (70283885)
|
Co-Investigator(Kenkyū-buntansha) |
NAGAYA Hisao 兵庫医科大学, 医学部, 助教 (60464343)
|
Co-Investigator(Renkei-kenkyūsha) |
TAGAWA Masatoshi 千葉県がんセンター, 病理研究部, 部長 (20171572)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 膀胱癌 / アデノウイルスベクター / 遺伝子治療 / CD46 / CAR / 腎臓癌 / アデノウイルス / CD46蛋白質 / 抗腫瘍効果 |
Research Abstract |
In this study, we examined whether the fiber knob substituted adenovirus vector enhance the therapeutic effect of gene therapy for human bladder cancer which do not have a significant effect on therapeutic outcome of adenovirus gene therapy. Our data showed the novel fiber knob substituted adenovirus vector, Ad5F35/MK, is more useful for the gene therapy of bladder cancer than the non fiber knob substituted Ad5/MK is for human bladder cancer in vitro and in vivo.
|
Report
(4 results)
Research Products
(18 results)